Thrombolytic therapy and proteolysis of Factor V

Journal of the American College of Cardiology

Volumn 30, Issue 3, 1997, Pages 716-724

  Tracy, Russell P ^a   Rubin, Deborah Z ^a   Mann, Kenneth G ^a   Bovill, Edwin G ^a   Rand, Matthew ^a   Geffken, Dominic ^a   Tracy, Paula B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030921192     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00230-1     Document Type: Review

References (44)

1. Jenny RJ, Mann KG. Factor V a prototype co-factor for vitamin K-dependent enzyme complexes in blood clotting . Baillieres Clin Haematol. 2:1989;919-944.
2. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem. 57:1988;915-956.
3. Mann KG. Normal Hemostasis. Kelley W. Textbook of Internal Medicine. 1992;1240-1245 J.B. Lippincott, New York.
4. Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem. 270:1995;1408-1415.
5. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 264:1987;4743-4753.
6. Omar MN, Mann KG. Inactivation of factor Va by plasmin. J Biol Chem. 262:1987;9750-9755.
7. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood. 73:1989;185-190.
8. Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue-type plasminogen activator a hematologic and pharmacologic study . Ann Intern Med. 103:1985;837-843.
9. Collen D, Bounameaux H, DeCock F, Lunen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation. 73:1986;511-517.
10. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA. 78:1981;1622-1627.
11. Nesheim ME, Mann KG. Thrombin-catalyzed activation of single-chain bovine factor V. J Biol Chem. 254:1979;1326-1338.
12. Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in plasma and platelets. Blood. 60:1982;59-67.
13. Bajaj SP, Rapaport SL, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem. 11:1981;397-405.
14. Owen WG, Jackson CM. Activation of prothrombin with Oxyuranus scutellatus scutellatus (Taipan snake) venom. Thromb Res. 3:1973;705-710.
15. Viskup RW, Tracy PB, Mann KG. The isolation of human platelet factor V. Blood. 69:1987;1468-1475.
16. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 320:1989;618-627.
17. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
18. Braunwald E, Knatterud GL, Passamani E. Announcement of protocol change in thrombolysis in myocardial infarction trial [letter]. J Am Coll Cardiol. 9:1987;467.
19. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
20. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial . Ann Intern Med. 115:1991;256-265.
21. Geffken DF, Keating FG, Kennedy MH, Cornell ES, Bovill EG, Tracy RP. The measurement of fibrinogen in population-based research studies on instrumentation and methodology . Arch Pathol Lab Med. 118:1994;1106-1109.
22. Clauss A. Gerinnungs-physiologische schnell-methode zur bestimmung des fibrinogens. Acta Haematol. 17:1957;237-246.
23. Merskey C, Lalezari P, Johnson AJ. A rapid, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med. 131:1969;871-875.
24. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost. 54:1985;684-697.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
26. Tracy RP, Monkovic D, Andrianorivo A, Calore JD, Mackay AM. The effect of pre-staining prior to immunoreaction during electrophoretic blotting. Electrophoresis. 8:1987;350-357.
27. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 237:1982;6556-6565.
28. Esmon CT. The subunit structure of thrombin-activated factor V. J Biol Chem. 254:1979;964-974.
29. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 29:1990;1118-1128.
30. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 19:1992;1065-1069.
31. Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 7:1986;1253-1262.
32. Gulba PC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction relevance for the success of therapy . Circulation. 83:1991;937-944.
33. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) trial - phase I hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase . J Am Coll Cardiol. 11:1988;1-11.
34. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 320:1989;352-357.
35. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 20:1992;513-519.
36. Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 67:1991;3-11A.
37. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992;101:131-9S.
38. Francis CW, Marder VJ. Mechanisms of fibrinolysis. Williams W, Beutler E, Erslev A, Lichtman M. Hematology. 3rd ed. 1983;1266-1276 McGraw-Hill, New York.
39. Sane D, Califf R, Topol E, Stump D, Mark D, Greenberg C. Bleeding during thrombolytic therapy for acute myocardial infarction mechanisms and management . Ann Intern Med. 111:1989;1010-1022.
40. Kasper W, Erbel R, Meinertz T, et al. Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction. J Am Coll Cardiol. 4:1984;357-363.
41. Williams WJ. Life span of plasma coagulation factors. Williams W, Beutler E, Erslev A, Lichtman M. Hematology. 3rd ed. 1983;1230-1238 McGraw-Hill, New York.
42. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 21:1993;1039-1047.
43. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 91:1994;3670-3674.
44. Collen DC, Lijnen HR. Staphlokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood. 84:1994;680-686.